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Background
In patients with severe aortic stenosis (AS), long-term data
tracking surgically induced beneficial effects of afterload
reduction on reverse LV remodeling are not available.
Echocardiographic data is available short term, but in lim-
ited fashion beyond one year. Cardiac MRI (CMR) offers
the ability to track changes in LV metrics with small num-
bers due to its inherent high spatial resolution and low
variability. Following aortic valve replacement (AVR) for
severe aortic stenosis there is initially marked improve-
ment in many LV reverse remodeling metrics. The durabil-
ity for such observations is explored.
Hypothesis
We hypothesize that progressive changes following aortic
valve replacement (AVR) are detectable by CMR and
changes in LV structure and function, triggered by AVR,
continue for an extended period following AVR.
Methods
Ten patients (67 ± 12 yrs, 6 female) with severe, but com-
pensated, AS underwent CMR pre-AVR and post AVR at 6
± 2 mo, 1 yr ± 2 mo, and up to 4 yrs ± 5 mo. LV mass index
(LVMI), LV geometry, volumetrics and EF were measured
(GE, EXCITE 1.5 T, Milwaukee, WI). A Kruskall-Wallis
one-way ANOVA was performed.
Results
All 10 pts survived AVR and underwent CMR at up to the
4-year time point (40 total time points). LVMI markedly
decreased at 6 months (157 ± 42 to 134 ± 32 g/m2, p <
0.005) and continued to trend down at 4 yrs (127 ± 32 g/
m2). Similarly, EF increased pre to post AVR (55 ± 22 to
65 ± 11%, (p < 0.05)) and continued trending upward,
remaining stable at years 1–4 (66 ± 11 vs. 65 ± 9%).
LVEDV index, initially high pre AVR, normalized post
AVR (83 ± 30 to 68 ± 11 ml/m2, p < 0.05) trending even
lower by yr 4 (66 ± 10 ml/m2). LV stroke volume
increased rapidly from pre to post AVR (40 ± 11 to 44 ± 7
ml) continuing to increase at 4 yrs (49 ± 14 ml, p = 0.3).
Most importantly, LVMI/volume, a 3D measure of LV
geometry, remained unchanged initially but over 4 yrs
markedly improved (1.07 ± 0.2 to 0.94 ± 0.24, p < 0.05)
all paralleling improvements in NYHA (3.2 ± 1.0 to 1.5 ±
1.1, p < 0.05).
Conclusion
After the initial beneficial effects imparted by AVR in
severe AS patients, there are, as expected, marked
improvements in LV reverse remodeling. We have shown,
via CMR, that surgically induced benefits to LV structure
and function, including favorable alterations in LV geom-
etry, are durable and, unexpectedly, show continued
improvement through 4 years post-AVR concordant with
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sustained improved clinical status. This supports down
regulation of both mRNA and MMP activity acutely with
robust suppression long term.Page 2 of 2
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